Federico C.
- Country
- Italy
- Department
- Centro Fibrosi Cistica
Research Overview
- Evaluation of VX-522 and Ivacaftor in Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy: A Phase 1/2 Dose-Escalation Study
- Evaluation of Safety, Tolerability, and Efficacy of Inhaled BI 3720931 Gene Therapy in Adults with Cystic Fibrosis Ineligible for CFTR Modulators
- Long-term Safety and Efficacy Evaluation of Inhaled Lentiviral Vector Gene Therapy BI 3720931 in Cystic Fibrosis Patients from Previous Clinical Trial
Data & Insights
Has run more than one trial at 11 of 165 partner sites.
Specializations
Respiratory Disease Management
This investigator specializes in the treatment of cystic fibrosis, with particular focus on innovative therapeutic approaches for managing this genetic condition.
- Pulmonary Function Assessment
- Long-term Disease Monitoring
- Respiratory Treatment Evaluation
Their work encompasses evaluation of novel inhaled therapeutics and assessment of pulmonary outcomes in cystic fibrosis patients.
Novel Therapeutics Development
The investigator focuses on examining emerging treatments for genetic respiratory disorders, including the evaluation of new pharmaceutical compounds.
- Safety and Tolerability Studies
- Drug Administration Protocols
- Therapeutic Combination Approaches
Their research includes assessment of both single and multiple-dose therapeutic regimens.
Clinical Outcomes Research
Expertise in conducting long-term safety monitoring and effectiveness studies for respiratory treatments.
- Patient Health Status Monitoring
- Treatment Response Assessment
- Extended Follow-up Studies
The investigator specializes in evaluating sustained therapeutic effects and long-term patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.